Analysis of pretreatment factors and PFS revealed that patients without cytoreductive nephrectomy (CN), and with bone metastasis, high C-reactive protein (CRP) levels and paraneoplastic symptoms at the initiation of ipilimumab and nivolumab treatment were significantly correlated with short PFS in the univariate analysis (Table 3). Here, CRP is linked to bone metastasis.